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INTRODUCTION
The percutaneous cardiopulmonary support system (PCPS)
has gained wide acceptance in circulatory support because it
produces favorable results and remarkable advances in catheters
and membrane oxygenators (1, 2). PCPS is currently used
for severe cardiac failure, cardiogenic shock, and/or postop-
erative cardiac support (3-5). Although PCPS can easily be
started using a heparin-coated circuit, a centrifugal pump,
and membrane oxygenators, some PCPS patients cannot be
easily weaned from its support. In addition, PCPS has been
associated with clinical problems, including left ventricular
afterload, limb ischemia, decreased platelet count, bleeding,
inguinal infection, and complications from multiple organ
failure (MOF) (6). Thus, determining the indicators for start-
ing and discontinuing PCPS remain clinically problematic.
To determine factors predicting the outcome of PCPS, we
retrospectively reviewed results of patients treated with PCPS
for severe cardiopulmonary failure.
MATERIALS AND METHODS
We retrospectively reviewed the medical records of patients
treated with PCPS at Yonsei University Health System bet-
ween November 2005 and December 2007. Our study fol-
lowed the guidelines of the Institutional Review Board of
Yonsei University College of Medicine (Yonsei IRB No. 4-
2007-0248).
PCPS system
The PCPS system consists of a hollow-fiber microporous
membrane oxygenator, a centrifugal pump, arterial and venous
cannulae, and standard 3/8-inch tubing. The blood-contact
surfaces of these components were heparin-coated. PCPS was
established with venous drainage (17 Fr or 19 Fr) from the
femoral vein (the tip of the tube was placed in the right atrium)
and arterial blood was basically returned to the femoral artery
using a 17 Fr or 19 Fr arterial cannula. We used a Capiox SP
Pump Controller Sp-101 and Capiox circuit (Terumo Co., To-
kyo, Japan). Initial PCPS flow ranged from 2.0 to 3.0 L/min/m2
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Earlier Application of Percutaneous Cardiopulmonary Support Rescues
Patients from Severe Cardiopulmonary Failure Using the APACHE III
Scoring System
Percutaneous cardiopulmonary support (PCPS) is a widely accepted treatment for
severe cardiopulmonary failure. This system, which uses a percutaneous approach
and autopriming devices, can be rapidly applied in emergency situations. We sought
to identify the risk factors that could help predict in-hospital mortality, and to assess
its outcomes in survivors. During a 2-yr period, 50 patients underwent PCPS for
the treatment of severe cardiopulmonary failure, and of those, 22 (44%) were clas-
sified as survivors and 28 (56%) as non-survivors. We compared the 2 groups for
risk factors of in-hospital mortality and to establish proper PCPS timing. Twenty
patients underwent PCPS for acute myocardial infarction, 20 for severe cardiopul-
monary failure after cardiac surgery, 7 for acute respiratory distress syndrome, and
3 for acute myocarditis. Multivariate analysis showed that an acute physiology, age,
and chronic health evaluation (APACHE) III score ≥50 prior to PCPS was the only
significant predictor of in-hospital mortality (P=0.001). Overall 18-month survival was
42.2%. Cox analysis showed patients with APACHE III scores ≥50 had a poor
prognosis (P=0.001). Earlier application of PCPS, and other preemptive strategies
designed to optimize high-risk patients, may improve patient outcomes. Identifying
patients with high APACHE scores at the beginning of PCPS may predict in-hospi-
tal mortality. Survivors, particularly those with higher APACHE scores, may require
more frequent follow-up to improve overall survival.
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to maintain optimal hemodynamics, adjusted for each patient.
Activated clotting time was maintained at 180-200 sec and a
heparin bolus was used at the time of cannulation followed by
a continuous intravenous infusion of heparin during PCPS use.
Indications for PCPS application
Patients with severe cardiac failure are indicated for PCPS
at our hospital if their peak systolic blood pressure is less than
80 mmHg and their cardiac index is less than 1.8 L/min/m2
for more than 30 min after the correction of hypovolemia,
hypoxemia, and acidosis while under maximal medical treat-
ment. PCPS is also indicated for rapid deterioration of car-
diac output that is unresponsive to intra-aortic balloon pump-
ing (IABP), in patients who could not be discontinued from
cardiopulmonary bypass after cardiovascular surgery, for res-
piratory arrest, and for acute respiratory distress syndrome
(ARDS). The decision to initiate and continue PCPS thera-
py was made by the physician in charge (Table 1).
Indications for PCPS termination
PCPS flow was gradually decreased while monitoring hemo-
dynamics through a transesophageal or transthoracic echocar-
diogram when terminating PCPS. If an indwelling Swan-
Ganz catheter was present, continuous cardiac output or pul-
monary artery pressure was maintained using a sufficient
preload of catecholamine followed by administration of the
required dose after hemodynamic stabilization. PCPS could
then be terminated when PCPS flow was between 1.5 and
2.0 L/min and the hemodynamics were stable, i.e., mean sys-
tolic blood pressure was greater than 80 mmHg, central ve-
nous pressure was less than 15 mmHg, and pulse pressure
was greater than 30 mmHg.
Prognostic factors for in-hospital mortality
The patients were divided into 2 groups: those who were
PCPS, percutaneous cardiopulmonary supporting system; AMI, acute
myocardial infarction; PCI, percutaneous coronary intervention; ARDS,
acute respiratory distress syndrome.
Variables
Non-
survivors
(n=28)
Survivors 
(n=22)
Postoperative cardiogenic shock (n=13) 9 4
Postoperative intractable arrhythmia (n=7) 4 3
AMI-PCI (n=11) 3 8
Pre-PCI cardiogenic shock (n=6) 3 3
Post-PCI cardiogenic shock (n=3) 2 1
Cardiogenic shock due to acute myocarditis (n=3) 2 1
Postoperative ARDS (n=1) 1 0
ARDS (n=6) 4 2
Table 1. Indications for PCPS
Values are expressed as mean±SD or as n (%).
OR, odds ratio; CI, confidence interval; BSA, body surface area; APACHE, acute physiology, age, and chronic health evaluation; CPR, cardiopulmonary
resuscitation; IABP, intraaortic balloon pump; CRRT, continuous renal replacement therapy; MRSA, methicillin-resistant Staphylococcus aureus; ICU,
intensive care unit.
Variables Non-survivors (n=28) Survivors (n=22) P value OR CI
Age (yr) 61.3±11.5 67.2±11.3 0.229
Gender, males, n (%) 18 (64.3) 12 (54.5) 0.379 3.425 0.515-22.727
BSA (m
2) 1.72±0.08 1.61±0.19 0.103
APACHE III score 64.9±14.8 46.5±10.2 0.004
Epinephrine (μ g/kg/min) 0.04±0.08 0.00±0.02 0.248
Norepinephrine (μ g/kg/min) 0.54±1.04 0.13±0.38 0.196
Dopamine (μ g/kg/min) 10.65±26.7 0.01±0.02 0.115
Dobutamine (μ g/kg/min) 8.68±14.12 0.41±1.50 0.098
CPR, n (%) 13 (46.4) 6 (27.3) 0.417 2.250 0.407-12.439
CPR time (min) 39.9±39.2 25.0±24.9 0.415
Surgery 15 (53.6) 5 (22.7) 0.042 3.923 1.132-13.602
Ischemic heart disease 17 (60.7) 18 (81.8) 0.131 0.343 0.092-1.289
IABP, n (%) 4 (14.3) 5 (22.7) 0.339 0.250 0.023-2.696
CRRT, n (%) 15 (53.6) 2 (9.1) 0.004
MRSA infection, n (%) 16 (57.1) 3 (13.6) 0.039 8.350 1.154-59.003
Preparation time (min) 19.1±14.4 20.6±9.0 0.812
Initial pump flow (L/min) 2.90±0.39 2.38±0.66 0.037
Total pump time (hr) 45.6±40.0 16.5±19.8 0.003
Ventilation time (day) 21.7±37.2 4.8±4.4 0.185
ICU stay (day) 24.7±36.5 10.7±7.1 0.260
Hospital stay (day) 26.9±36.0 28.0±27.5 0.935
Table 2. Univariate analysis of in-hospital mortality 1066 S.-W. Song, H.-S. Yang, S. Lee, et al.
successfully weaned from PCPS and discharged from the ICU,
and those who eventually died in hospital. The two groups
were compared with respect to age, gender, body surface area,
cardiopulmonary resuscitation (CPR), CPR time, surgery,
ischemic heart disease, use of IABP, use of continuous renal
replacement therapy, and whether or not the patient had me-
thicillin-resistant Staphylococcus aureus (MRSA) infection. The
PCPS flow, acute physiology, age, and chronic health evalu-
ation (APACHE) III score, and dose of catecholamine used
(epinephrine, norepinephrine, dopamine, and dobutamine)
over the 72-hr period beginning at the time PCPS began
were also compared between the 2 groups (Table 2).
Measurement of APACHE score
The APACHE III prognostic system, which was developed
in the United States based on data collected from 17,440 ICU
admissions at 42 ICUs, consists of 2 components: an APA-
CHE III score, which can provide initial risk stratification
for severely ill hospitalized patients within independently
defined patient groups; and an APACHE III predictive equa-
tion, which uses the APACHE III score and reference data
on major disease categories and treatment locations immedi-
ately prior to ICU admission to provide risk estimates for in-
hospital mortality of individual ICU patients. A 5-point in-
crease in APACHE III score (range, 0 to 299) has been shown
to be independently associated with a statistically significant
increase in the relative risk of hospital death within each of
the 78 major medical and surgical disease categories. All of
the 50 patients who required PCPS were scored according
to the APACHE III prognostic system (7). APACHE III scores
were calculated by summing the acute physiological score, age
score, and chronic health evaluation scores. Acute physiolog-
ical scores were calculated by summing scores for 17 variables
before initiating PCPS. APACHE III scores were recorded
for 72 hr after PCPS application. 
Statistical analysis
Data were analyzed using SPSS for Windows, version 12.0
(SPSS, Inc, Chicago, IL, U.S.A). Categorical variables were
compared using chi-square or Fisher’s exact tests, and con-
tinuous variables were compared using Student’s t or Mann-
Whitney U tests as appropriate. The risk of ICU mortality
associated with selected factors was evaluated using stepwise
binary logistic regression analysis to estimate odds ratio (OR)
and their 95% confidence interval (CI). Continuous variables
were dichotomized using the median values as cutoff. A P
value ≤0.05 according to univariate analysis was the crite-
rion for submitting variables to the model. Goodness of fit was
assessed using the Hosmer and Lemeshow chi-square test.
The relative risk, defined as the ratio of incidence among ex-
posed to that among non-exposed subjects, was used to sum-
marize the strength of the association between risk factors
and pulmonary complications. The 95% CIs of the relative
risk were calculated using Miettinen’s test-based approach.
Unless otherwise stated, results are expressed as mean±stan-
dard deviation (SD) for continuous variables, and as percent-
ages for categorical variables. Estimates of survival were ob-
tained using the Kaplan-Meier method. Cox proportional
hazards methodology was used to model the probability of
survival as a function of time and to assess differences in sur-
vival associated with various patient characteristics. Risk ratios
(also referred to as hazard ratios) and 95% CIs are presented
to indicate significance in multivariate models. Multivariate
modeling was initially executed using forward selection, fol-
lowed by confirmation using backward selection. No vari-
able was forced to remain in a model, and variables associat-
ed with a Pvalue ≤0.05 were maintained in the model. Sta-
tistical comparisons were made using chi-square analysis or
analysis of variance (ANOVA) followed by Fisher’s protect-
ed least significant difference. 
RESULTS
In total, 50 patients (30 men, 20 women), of mean age 64.6
±11.6 yr (range, 46 to 92 yr), were treated with PCPS for
severe cardiopulmonary failure in the ICU. Of the 20 patients
who had undergone cardiovascular surgery, 15 used cardiopul-
monary bypass (4 on-pump coronary artery bypass grafting,
4 valve surgery, 4 aortic surgery, 3 congenital heart surgery;
mean total cardiopulmonary bypass time, 215 min; mean
aortic cross clamp time, 175 min), 3 underwent off-pump
coronary artery bypass grafting, 1 pericardiectomy, and 1 peri-
cardial window formation. Twenty patients suffered from
acute myocardial infarction with unstable hemodynamics.
The indications for PCPS are listed in Table 1.
Nineteen patients (38%) went into cardiac arrest prior to
PCPS application, 3 went into cardiogenic shock before per-
cutaneous coronary intervention (PCI), 3 after PCI, 11 after
cardiac surgery (including 1 patient with postoperative int-
ractable arrhythmia), and 2 had ARDS. The mean CPR time
before PCPS application was 40.7±42.6 min (range, 7 to
144 min). Intraaortic balloon pumps were needed in 9 patients
(18%). Renal failure was evident in 17 patients (34%) who
were treated with continuous infusions of diuretics, low-dose
dopamine, and eventually renal replacement therapy (hemo-
dialysis in 16 patients, and peritoneal dialysis in 1 patient).
Invasive nutritional support was used in almost all patients.
Nineteen patients (38%) were diagnosed with a clinically
significant MRSA infection at some stage during hospital-
ization.
Patient outcomes
PCPS was successfully terminated in 22 patients (44%).
Of 28 patients (56%) in whom PCPS could not be terminat-Earlier Application of Percutaneous Cardiopulmonary Support 1067
ed, 9 died of persistent cardiac failure, 9 of MOF, 9 of sepsis,
and 1 of respiratory failure due to ARDS. For all patients, the
mean duration of PCPS support was 29.1±33.0 hr (range,
18 min to 126.2 hr) and the mean ICU stay was 17±25
days (range, 2 to 110 days). Bleeding complications occurred
in 2 patients, with 1 each having upper gastrointestinal tract
bleeding and hemopericardium. Lower limb ischemia occurred
in 2 patients as a thrombotic complication associated with
the insertion of the arterial cannula. One of these patients
had to undergo a below-knee amputation, despite a Fogarty
thromboembolectomy in the right popliteal artery. The other
patient required transmetatarsal amputation of the left foot.
Clinical prognostic factors in patients undergoing PCPS
Twenty one variables were examined for possible associa-
tions with hospital mortality (Table 2). Variables first under-
went univariate analysis and then underwent multivariate
analysis, adjusting for confounders, if they were found to be
significant. Univariate analysis showed that the following 6
variables were associated with in-hospital mortality: a higher
APACHE III score, surgery, continuous renal replacement
therapy, MRSA infection, initial PCPS flow, and a longer total
pump time. The incidence of cardiac arrest prior to PCPS
application did not differ between survivors and non-survi-
vors, nor did the incidence of IABP insertion (P=0.339). Figs.
1, 2 show the serial change of catecholamine dose required
(dopamine, dobutamine, epinephrine, and norepinephrine).
Non-survivors required a higher dosage of catecholamine for
the first 72 hr after initiation of PCPS, but the difference was
not significant (P>0.05). Fig. 3 shows the change of APACHE
III scores over 72 hr. The 2 groups showed significant differ-
ences on a repeated generalized linear model (P=0.025).
Stepwise forward binary logistic regression analysis iden-
tified that an APACHE III score 50 or greater prior to PCPS
was the most significant factor related to prognosis (OR,
Survivors
Fig. 1. Serial catecholamine dose administered during PCPS to survivors and nonsurvivors. (A) Dopamine, (B) Dobutamine. The two groups
did not differ significantly using a repeated generalized linear model (P>0.05).
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14.351; CI, 3.127-72.338; P=0.001). This result was con-
firmed using a stepwise, backward binary logistic regression
analysis. Patients with an APACHE III score higher than
50 on the initial day of PCPS had an in-hospital mortality
of 73.5% (25 of 34) (Table 3).
Survival
Patient follow up was complete (median follow-up, 12.7
months; range, 2.0 to 19.6 months). Overall 18-month sur-
vival was 42.2%. Cox proportional hazard regression analy-
sis showed that patients with APACHE III scores ≥50 had
a poor prognosis. Overall survival at 18 months was 78.8%
for patients with APACHE scores <50 and 26.1% for patients
with APACHE III scores ≥50 (P=0.001) (Fig. 4). At last
follow up, 11 patients were in the NYHA functional class I,
7 patients in class II, and 4 patients in class III.
DISCUSSION
Recent developments in medical engineering have resulted
in innovations that have transformed PCPS into a compact,
battery-powered, portable heart-lung machine that can be
implemented rapidly in any area of the hospital using thin-
walled cannulas inserted via the femoral vessels (8). Because
PCPS is a portable and powerful resuscitative tool, it has been
effectively used for the treatment of cardiac failure in various
situations, including postcardiotomy low cardiac output syn-
drome (6, 9), prolonged cardiopulmonary resuscitation (10),
and acute myocardial infarction (10). In addition, PCPS has
been used prophylactically in high-risk coronary patients need-
ing percutaneous stent revascularization (12). When used for
cardiac arrest during coronary intervention in the catheteri-
zation laboratory, PCPS has demonstrated a late survival rate
ranging between 57% and 64% (13-15) and a late survival
rate ranging between 56% and 66.7% for postoperative low
output syndrome (9).
Between February 1998 and October 2005, before the intro-
duction of the PCPS system, we used an extracorporeal mem-
brane oxygenator (ECMO), but the outcomes were dismal,
with an ECMO in-hospital mortality rate of 91.6% (11 of
12) (data not shown here). After switching to the PCPS sys-
tem, however, this rate was reduced significantly, to 56% (28
of 50). However, PCPS is limited in its ability to promote
the recovery of left ventricular function in the presence of
seriously damaged myocardium. 
To clarify the effectiveness of PCPS, we analyzed the back-
ground, characteristics, and the prognosis of patients who
underwent PCPS for the treatment of severe cardiopulmonary
failure due to various causes, including postcardiac surgery,
ARDS, acute myocardial infarction, and acute myocarditis.
We found that a higher APACHE III score at the beginning
of PCPS, higher initial pump flow, and longer duration of
bypass time were predictors of poor outcome of PCPS. Al-
No., number; OR, odds ratio; CI, confidence interval; APACHE, acute physiology, age, and chronic health evaluation.
Variables Category
No. (%) 
non-survivors
No. patients OR 95% CI P value
APACHE III score ≥50 34 25 (73.5) 14.35 3.13-72.34 0.001
<50 15 3 (20.0) 1
Table 3. Multivariate logistic regression analysis of in-hospital mortality 
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Fig. 4. Overall survival in patients with PCPS relative to initial APACHE
III scores. Overall survival at 18 months was 87.5% for patients with
APACHE scores <50 and 28.8% for patients with APACHE III scores
≥50 (P=0.001).
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though PCPS was initially used to save the lives of patients
with severe cardiac failure who required an extreme dose of
catecholamine and in whom IABP was not sufficient to main-
tain circulation, indications for PCPS have widened. We found
that APACHE III score ≥50 and serial changes in APACHE
III score during the first 72 hr were predictive of in-hospital
mortality. 
Then, how can we reduce PCPS in-hospital mortalities?
This study revealed several factors could predict PCPS mor-
tality. To improve APACHE III scores at the beginning of
PCPS, an earlier application of PCPS would be helpful to
break a vicious circle and reduce initial pump flow, and the
duration of bypass time. Since October 2005, our policies
for PCPS application have changed in several aspects. We
performed early orotracheal intubation and full sedation for
several days, especially in ARDS patients, with early, low-
dose steroid therapy as guidelines indicated. When deciding
to apply PCPS, we did not hesitate to apply PCPS to patients
who suffered from severe cardiopulmonary failure with hemo-
dynamic compromise. If needed, early bedside tracheotomies
were performed. Ultimately, we have undertaken aggressive
and early preemptive management to break this vicious circle.
We observed 2 instances of PCPS-related bleeding and 2
thrombotic complications. Before using the PCPS system,
cannulas were not heparin-coated, requiring us to maintain
an activated clotting time of 250 sec or greater, thus leading
to a 50% (6/12, data not shown here) incidence of bleeding
complications. Use of heparin-coated cannulas and tubes has
enabled us to maintain an activated clotting time of about
180-200 sec. Thrombotic complications after removing PCPS
cannulas may be prevented by routine performance of distal
lower limb perfusion at the beginning of PCPS. Moreover,
when removing the PCPS catheter, the proximal and distal
parts of the femoral artery should be clamped, a sufficient
amount of blood should be flushed to remove any thrombus
in the lumen, and the femoral artery should be repaired. 
Among the limitations of this study were its retrospective
design and the presence of typical institutional biases regard-
ing patient selection. However, we sought to analyze a rela-
tively homogenous population by using patients with cardio-
vascular disease. Although survival from PCPS was the pri-
mary end point, we should have evaluated other significant
patient outcomes after discharge, including comfort, advance-
ment of oral nutrition, improved patient-family communica-
tion, and simplified nursing care. Since these measurements
could not be easily abstracted and quantified, these analyses
were not undertaken.
In conclusion, our findings indicate that earlier application
of PCPS, which lowers initial APACHE III scores, as well as
other preemptive strategies designed to optimize high-risk
patients, may improve patient outcomes. Identifying patients
with high APACHE scores at the beginning of PCPS may
predict the risk of in-hospital mortality. Survivors from PCPS,
particularly those with higher initial APACHE scores, may
require more careful and frequent short-term follow up.
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